Receipt of BNT162b2 Vaccine and COVID-19 Ambulatory Visits in US Children Younger Than 5 Years

Sara Y Tartof; Timothy B Frankland; Jeff M Slezak; Laura Puzniak; Bradley K Ackerson; Luis Jodar; John M McLaughlin

doi:10.1001/jama.2023.17473

Receipt of BNT162b2 Vaccine and COVID-19 Ambulatory Visits in US Children Younger Than 5 Years

JAMA. 2023 Oct 3;330(13):1282-1284. doi: 10.1001/jama.2023.17473.

Authors

Sara Y Tartof¹, Timothy B Frankland², Jeff M Slezak¹, Laura Puzniak³, Bradley K Ackerson⁴, Luis Jodar³, John M McLaughlin³

Affiliations

¹ Kaiser Permanente Southern California Department of Research & Evaluation, Pasadena.
² Kaiser Permanente Hawai'i Center for Integrated Health Care Research, Honolulu, Hawai'i.
³ Pfizer Inc, Collegeville, Pennsylvania.
⁴ Southern California Permanente Medical Group, Harbor City.

No abstract available

Plain language summary

This study examines the association of the receipt of wild-type BNT162b2 vaccine with medically attended COVID-19 outcomes among children younger than 5 years in the US.

MeSH terms

Age Factors
Ambulatory Care / statistics & numerical data
BNT162 Vaccine* / therapeutic use
COVID-19* / epidemiology
COVID-19* / prevention & control
Child, Preschool
Humans
United States / epidemiology
Vaccination / statistics & numerical data

Substances

BNT162 Vaccine